RA Capital Management, a multi-stage investment manager, led a $132m Series B funding round in Rivus Pharmaceuticals, a developer of controlled metabolic accelerators, with participation from Bain Capital Life Sciences, BB Biotech, Longitude Capital, Medicxi and RxCapital. "We have an exceptional group of investors who share our vision for bringing a new class of treatments to patients with obesity and cardio-metabolic disease. Following encouraging data from our Phase 2a clinical trial in patients with obesity, this financing enables us to advance development of HU6 and a pipeline of Controlled Metabolic Accelerators to address a range of cardio-metabolic conditions," Allen Cunningham, Rivus Pharmaceuticals President and CEO.